T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease

Soriano, 2020, Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet Respir Med, 8, 585, 10.1016/S2213-2600(20)30105-3 Soler-Cataluña, 2005, Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease, Thorax, 60, 925, 10.1136/thx.2005.040527 Alcázar Navarrete, 2019, Patients with chronic obstructive pulmonary disease exacerbations: recommendations for diagnosis, treatment and care, Arch Bronconeumol, 55, 478, 10.1016/j.arbres.2019.02.020 Miravitlles, 2021, Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable, Arch Bronconeumol Vogelmeier, 2017, Informe 2017 de la iniciativa global para el diagnóstico tratamiento y prevención de la enfermedad pulmonar obstructiva crónica: resumen ejecutivo de GOLD, Arch Bronconeumol, 53, 128, 10.1016/j.arbres.2017.02.001 Agusti, 2010, Characterisation of COPD heterogeneity in the ECLIPSE cohort, Respir Res, 11, 122, 10.1186/1465-9921-11-122 Brightling, 2019, Airway inflammation in COPD: progress to precision medicine, Eur Respir J, 54, 1900651, 10.1183/13993003.00651-2019 Greulich, 2018, Blood eosinophils as a marker of eosinophilic exacerbations in COPD, Lancet Respir Med, 6, e17, 10.1016/S2213-2600(18)30095-X Alcázar-Navarrete, 2018, Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD, Eur Respir J, 51 Zeiger, 2018, Relationship of blood eosinophil count to exacerbations in chronic obstructive pulmonary disease, J Allergy Clin Immunol Pract, 6, 944, 10.1016/j.jaip.2017.10.004 Zysman, 2017, Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD, Int J Chronic Obstr Pulmon Dis, 12, 1819, 10.2147/COPD.S129787 Oshagbemi, 2017, Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts, Am J Respir Crit Care Med, 195, 1402, 10.1164/rccm.201701-0009LE Harries, 2020, Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis, Respir Res, 21, 3, 10.1186/s12931-019-1268-7 Divo, 2012, Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 186, 155, 10.1164/rccm.201201-0034OC Agustí, 2012, Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations?, COPD, 9, 492, 10.3109/15412555.2012.692409 García-Río, 2013, Espirometría, Arch Bronconeumol, 49, 388, 10.1016/j.arbres.2013.04.001 ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912–30. doi:10.1164/rccm.200406-710ST. Horváth, 2017, A European Respiratory Society technical standard: exhaled biomarkers in lung disease, Eur Respir J, 49, 1600965, 10.1183/13993003.00965-2016 Leung, 2019, Introduction to precision medicine in COPD, Eur Respir J, 53, 1802460, 10.1183/13993003.02460-2018 Wedzicha, 2014, Acute COPD exacerbations, Clin Chest Med, 35, 157, 10.1016/j.ccm.2013.11.001 Vedel-Krogh, 2016, Blood eosinophils and exacerbations in chronic obstructive, Am J Respir Crit Care Med, 193, 965, 10.1164/rccm.201509-1869OC Miravitlles, 2021, Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study, Arch Bronconeumol, 57, 13, 10.1016/j.arbres.2019.12.015 Singh, 2020, Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials, Respir Res, 21, 1, 10.1186/s12931-020-01482-1 Bafadhel, 2018, Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials, Lancet Respir Med, 6, 117, 10.1016/S2213-2600(18)30006-7 McDowell, 2021, The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study, Lancet Respir Med, 10.1016/S2213-2600(21)00004-7